Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON21320
NL-OMON21320
Completed
Not Applicable

Efficacy of peripherally targeted inhaled rhDNase for persistent obstructive asthma in childhood.

ErasmusMC Rotterdam0 sites60 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsasthma with persistent obstructive pulmonary function.

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
asthma with persistent obstructive pulmonary function.
Sponsor
ErasmusMC Rotterdam
Enrollment
60
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

  1. Fuchs, H.J., et al., Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med, 1994. 331(10): p. 637-42. 2. King, M., et al., Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med, 1997. 156(1): p. 173-7. 3. Hodson, M.E. and P.L. Shah, DNase trials in cystic fibrosis. Eur Respir J, 1995. 8(10): p. 1786-91. 4. Greally, P., Human recombinant DNase for mucus plugging in status asthmaticus. Lancet, 1995. 346(8987): p. 1423-4 5. Durward, A., V. Forte, and S.D. Shemie, Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus. Crit Care Med, 2000. 28(2): p. 560-2.
Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
ErasmusMC Rotterdam

Eligibility Criteria

Inclusion Criteria

  • •1\. Age 6 – 18 years;
  • •2\. Asthma diagnosed according to GINA guidelines;

Exclusion Criteria

  • •1\. Asthma exacerbation with hospital admission in last 3 months;
  • •2\. Intensive Care Unit (ICU) admission for asthma within the last year;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Peripheral targeting of inhaled rhDNase in stable CF patients.Cystic Fibrosis, rhDNase (Pulmozyme), inhalation, airways.
NL-OMON23855Investigator initiated study.Initiator: Harm Tiddens, M.D. PhD.ErasmusMC - Sophia Children's Hospital50
Completed
Not Applicable
DIEPTE-study: DNase Inhalation in cf Exacerbations, Peripherally Targeted.
NL-OMON25231Roche Nederland B.V.40
Active, not recruiting
Not Applicable
Efficacy of peripherally targeted inhaled rhDNase for persistent obstructive asthma in childhoodAsthma is a chronic inflammatory disorder in which many cells play a role, in particular mast cells, eosinophils and T lymphocytes. In susceptible individuals this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness and cough. These symptoms are usually associated with widespread but variable airflow limitation that is at least partly reversible either spontaneously or with treatment.MedDRA version: 8.1Level: LLTClassification code 10003553Term: Asthma
EUCTR2006-002337-20-NLErasmus Medical Centre Rotterdam60
Completed
Not Applicable
Efficacy of peripherally targeted inhaled rhDNase for persistent obstructive asthma in childhoodObstructive pulmonary function, asthmaRespiratoryObstructive pulmonary disease, asthma
ISRCTN71537084Erasmus Medical Center (The Netherlands)60
Completed
Not Applicable
Efficacy of Inhaled RhDNase in Mechanically Ventilated Pediatric Patients with an Atelectasis.Atelectasis during mechanical ventilation.
NL-OMON21415Erasmus Medical Center, Sophia Children's Hospital. Dr. Molewaterplein 60, 3015 GJ Rotterdam 80